Tikun Olam Europe Launches First Medical Cannabis Exports from Greece
Greek Medical Cannabis Makes History wiht First Export to Switzerland
Athens, Greece - In a major breakthrough for the burgeoning greek medical cannabis industry, Tikun Olam Europe, the nation’s first licensed medical cannabis company, has achieved a historic milestone: the first export of finished medical cannabis products from Greece. This landmark shipment, destined for Switzerland, marks the beginning of Tikun Olam Europe’s international expansion and positions Greece as a potential leader in the European medical cannabis market.
The export,a collaboration with Swiss pharmaceutical company MediCrops AG,includes dried flower products cultivated from tikun Olam’s signature cannabis strains. These strains, developed using advanced scientific practices, are already available to patients in the Greek market and are known for their therapeutic efficacy.
“Our first export represents a historic milestone, not only for Tikun Olam Europe but also for our country,” said Nikos Beis, CEO of Tikun Olam Europe. “It demonstrates that Greece can lead in international markets with innovative medical cannabis products manufactured under the highest safety and quality standards.”
Tikun Olam Europe’s state-of-the-art facilities in Corinth are certified according to stringent EU-GMP (Good manufacturing Practices) and GACP (Good Agricultural and Collection Practices) standards, ensuring the highest level of quality control throughout the production process.
This initial export is just the beginning for Tikun Olam europe. The company plans to expand it’s product portfolio to include sublingual oil drops, further enhancing therapeutic options for patients.Looking ahead, Tikun Olam Europe has set its sights on key European markets like the United Kingdom and Germany, aiming to establish a strong presence across the continent.
Ivan mestrangelo,Chairman of MediCrops AG,expressed his enthusiasm for the partnership: “We are proud to collaborate with Tikun Olam Europe,a pioneer in evidence-based medical cannabis. This partnership is a game-changer for the Swiss market, where we are committed to advancing patient access to high-quality cannabis-based treatments.”
The integration of Tikun Olam’s products into MediCrops AG’s comprehensive distribution network, which includes a telemedicine platform, licensed pharmacy, and dedicated cannabis treatment clinics, ensures Swiss patients receive the highest standard of care.
This groundbreaking collaboration not only strengthens the Swiss medical cannabis market but also sets a precedent for responsible and accessible cannabis-based therapies in healthcare.
Greek Medical Cannabis Makes ancient Debut on the International Stage
On the heels of a landmark achievement, Tikun Olam Europe , greeces first licensed medical cannabis company, has successfully executed the nation’s first export of finished medical cannabis products. This inaugural shipment, bound for Switzerland, signals the commencement of Tikun Olam Europe’s global expansion and establishes Greece as a potential frontrunner in the European medical cannabis landscape.
The export, a collaborative effort with Swiss pharmaceutical company, MediCrops AG , comprises dried flower products cultivated from Tikun Olam’s proprietary cannabis strains. These strains,developed leveraging advanced scientific methodologies,are already accessible to patients within the Greek market and are renowned for their therapeutic efficacy.
“This constitutes a watershed moment, not only for Tikun Olam Europe but for our nation as well,” stated Nikos Beis, CEO of Tikun Olam Europe. “It underscores Greece’s capacity to lead in international markets with innovative medical cannabis products adhering to the highest safety and quality standards.”
Manufactured within Tikun Olam Europe’s state-of-the-art facilities in Corinth, these products are certified in accordance with stringent EU-GMP (Good Manufacturing Practices) and GACP (Good Agricultural and Collection Practices) standards, guaranteeing meticulous quality control throughout the production process.
Beyond this inaugural export, Tikun Olam Europe envisions expanding its product line to include sublingual oil drops, thereby broadening therapeutic options for patients. The company’s sights are set on key European markets such as the United Kingdom and Germany, aiming to establish a robust presence across the continent.
Ivan Mestrangelo, Chairman of MediCrops AG, expressed his enthusiasm for the partnership: “We are honored to collaborate with Tikun Olam Europe, a pioneer in evidence-based medical cannabis. This partnership is transformative for the Swiss market, where we are dedicated to advancing patient access to high-quality, cannabis-based treatments.”
The integration of Tikun Olam’s products into MediCrops AG’s extensive distribution network, which encompasses a telemedicine platform, licensed pharmacy, and specialized cannabis treatment clinics, ensures that Swiss patients receive the highest standard of care.
This groundbreaking collaboration not only strengthens the Swiss medical cannabis market but also sets a precedent for responsible and accessible cannabis-based therapies in healthcare.